Patent ID: 11945858
Assignee: NATIONAL RESEARCH COUNCIL OF CANADA
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An antibody or antigen-binding fragment that binds specifically to loop 3 of a domain I (DI) of a Nav 1.7 polypeptide, and which inhibits the flux of Na+ through an hNAv 1.7 channel,
wherein the antibody comprises three variable heavy domain complementarity determining regions (CDR)(CDR H1, H2 and H3), and three variable light domain CDR (CDR L1, L2 and L3), said CDR H1, H2, H3, L1, L2, and L3 comprising the amino acid sequences:
CDR H1: GYTFTNYW (SEQ ID NO:7),
CDR H2: INPSNGRA (SEQ ID NO:8),
CDR H3: ARSPYGYYDY (SEQ ID NO:9),
CDR L1: QSLLHSNGNTY (SEQ ID NO:13),
CDR L2: KVS (SEQ ID NO:14), and
CDR L3: SQITHVPLT (SEQ ID NO:15); respectively;

or
CDR H1: GFSLSRYN (SEQ ID NO:75),
CDR H2: IWGGGST (SEQ ID NO:76),
CDR H3: ARNGANWDWFAY (SEQ ID NO:77),
CDR L1: QSLLYSSNQKNY (SEQ ID NO:80),
CDR L2: WAS (SEQ ID NO:81), and
CDR L3: QQYYSYPFT (SEQ ID NO:82), respectively;

or
CDR H1: GYTFTTYW (SEQ ID NO: 85),
CDR H2: INPSNGRA (SEQ ID NO:86),
CDR H3: LRSLGYFDY (SEQ ID NO:87),
CDR L1: QSLVHSNGNTY (SEQ ID NO:90),
CDR L2: KVS (SEQ ID NO:91), and
CDR L3: SQSTHVPYT (SEQ ID NO:92), respectively;

or
CDR H1: GFTFRSYA (SEQ ID NO:95),
CDR H2: ISSGGST (SEQ ID NO:96),
CDR H3: ARGYDGYYERIWYYAMDY (SEQ ID NO:97),
CDR L1: QNVGTI (SEQ ID NO:100),
CDR L2: SAS (SEQ ID NO:101), and
CDR L3: QQYNTYPLT (SEQ ID NO:102), respectively;

and
wherein said antigen-binding fragment comprises three variable domain complementarity determining regions (CDR)(CDR 1, 2 and 3), comprising the amino acid sequences
CDR 1: GFAFSSAP (SEQ ID NO:39),
CDR 2: IESDQDHTI (SEQ ID NO:40), and
CDR 3: QKRGEKKT (SEQ ID NO:41), respectively.